Answers are grounded in this paper and cite their sources.
Methicillin-resistant Staphylococcus aureus (MRSA) has become a significant acute and chronic respiratory pathogen. While vancomycin is effective against MRSA, its relatively poor penetration into lung secretions and dose-limiting renal toxicity make it less effective in the respiratory setting. As inhaled administration of vancomycin would overcome these limitations, we developed a dry powder formulation suitable for inhalation (AeroVanc).
No takes yet. Share an insight, caveat, or question.
Waterer et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: